HUTCHMED Closes License Deal With GSK Outside China
HUTCHMED says customary closing conditions have been completed for its license of a KRAS-EGFR-antibody conjugate therapy to GSK outside China.
Story updates
12:04:13 AM UTC
SquawkNews
HUTCHMED closed an exclusive license giving a GSK subsidiary rights outside Greater China to HMPL-A830. HUTCHMED expects a $110M upfront and up to $1.185B in milestones, plus tiered royalties; Phase I global study began in Sep 2026.Material DetailsContext by AI AnalystThis is an early-stage partner…
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) said on Oct. 20, 2026, that the license deal with GSK outside China has closed. The company said the closing followed its September 3, 2026 announcement and the completion of customary closing conditions, including…